CD8A and myeloid sarcoma: Given the heterogeneity and complexity of CD8+ T cell subpopulations, none of the twenty-three disease-modifying therapies approved by the U.S. Food and Drug Administration was specifically developed to target CD8+ T cells for treating MS.